Closing remarks Incretin-based AOM are currently in the spotlight as the most efficacious weight loss treatment to date 113 , exhibiting also beneficial effects on the complications of excess adiposity such as T2D, cardiovascular disease, heart failure, MASLD, OSA and possibly others
On a $400 monthly tirzepatide expense, HSA/FSA usage saves $88-$148 per month compared to after-tax dollars
The introduction of patiromer and SCZ into clinical practice represents a significant advancement in the management of hyperkalemia, particularly in HF patients who require ongoing treatment with RAASi and MRAs
Underlying Health Conditions Are Slowing Results Certain medical conditions can make weight loss more challenging
Clear triggers for contact ensure timely intervention to preserve safety and therapeutic benefit
Optimizing therapeutic outcomes with oral semaglutide requires a comprehensive approach that extends beyond simply taking the medication